real-time news and commentary for investors
Tuesday, Jan 29
More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings...
More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings climbed 65% on higher demand for its clinical R&D services and data analysis. Service revenue rose 27% to $422.1M, with newly-acquired Liquent contributing $400K in the quarter. Backlog at the end of December was approximately $4.54B, up 21.4% Y/Y. It also raises FY guidance, now expecting to earn $1.48 to $1.56 per share, with consolidated service revenue between $1.695B and $1.710B. Shares +3.4% AH.